Also, knocking down Lkb1 could partially recover cell death caused by Par3L deletion, suggesting that suppression of the Lkb1/AMP-activated protein kinase (AMPK) pathway is necessary for colorectal cancer cell survival, and that Par3L inhibition may be a novel therapeutic avenue [38]. Here, STK11 is linked to colorectal cancer.